Revolutionizing Cardiovascular Diagnostics: Cardiex at ARTERY 24

This year’s ARTERY 24 meeting was a convergence of cutting-edge cardiovascular research, clinical practice, and innovative technologies. Held at the National Museum in Cardiff, Wales, on the 10th and 11th of October, ARTERY 24 provided a unique platform for global leaders to share their latest findings on arterial function and vascular health. Cardiex was proud to be an exhibitor and a contributor to the research presentations, reaffirming our commitment to transforming cardiovascular health through science and innovation.

Highlighting the Role of Pulse Wave Velocity

During the conference, a significant emphasis was placed on pulse wave velocity, which is now integrated with abnormality thresholds into the 2023 ESC and ESH guidelines for hypertension management. During the ARTERY/VascAgeNet session, “Vascular ageing translation to practice: Mind the Gaps and Follow the Trends!”, the conversation gained momentum as speakers discussed integrating more pulse waveform measures, such as pulse pressure amplification. This promising dialogue, driven by the recent inclusion of pulse pressure in the ESH 2023 guidelines, underscores the growing evidence linking vascular biomarkers with risk outcomes—an influence likely to be further reflected in future guidelines.

Pioneering Research on Pregnancy Complications

Our Research Associate, Gisele Bentley, also presented findings on our current research in predicting pregnancy complications, such as preeclampsia, using vascular biomarkers. Pregnancy complications are usually identified in the third trimester, limiting early and simple interventions. Our findings indicate that as early as the first trimester, pulse wave velocity is consistently higher and less variable in pregnancies with complications compared to healthy pregnancies. These results highlighted the importance of Cardiex technologies in identifying early arterial changes that traditional blood pressure may miss. This work sparked dynamic discussions with researchers, clinicians, and industry professionals alike.

Showcasing Noninvasive Cardiovascular Solutions

We had the opportunity to showcase Cardiex technology, a suite of noninvasive cardiovascular solutions designed to provide deeper insights into arterial health. Our flagship product, the SphygmoCor® XCEL, has long been trusted by researchers and clinicians for its ability to measure central vascular biomarkers such as pulse wave velocity, central blood pressure, and other central pulse waveform parameters—key indicators in cardiovascular risk assessment. Visitors to our booth experienced firsthand how our devices integrate seamlessly into clinical and research workflows, as well as demonstrations of the newly released CONNEQT Pulse biometric monitor. This new personal arterial health monitor is the company’s first consumer offering that will empower users to monitor heart and vascular health at home with ease.

Empowering Personalized Cardiovascular Health

The future of cardiovascular health is increasingly personalized, and we working to empower healthcare providers and patients with the tools to improve heart health at the individual level. Our commitment to innovation, supported by our involvement in leading scientific forums like ARTERY 24, ensures that we continue to push the boundaries of what’s possible in cardiovascular diagnostics.

We left ARTERY 24 energized and inspired, reaffirming our belief that the future of cardiovascular care lies in understanding the nuances of arterial health. As we continue to collaborate with global leaders in the field, Cardiex remains dedicated to providing innovative solutions that empower both clinicians and patients and improve lives.